Open Access
Med Sci (Paris)
Volume 37, Number 10, Octobre 2021
Page(s) 882 - 887
Section M/S Revues
Published online 14 October 2021
  1. Santé publique France. Étude ESTEBAN 2014–2016 – Chapitre corpulence : stabilisation du surpoids et de l’obésité chez l’enfant et l’adulte. [Google Scholar]
  2. Bajos N, Wellings K, Laborde Cet al. Sexuality and obesity, a gender perspective : results from French national random probability survey of sexual behaviours. BMJ 2010 ; 340 : c2573. [PubMed] [Google Scholar]
  3. Brill MJ, Diepstraten J, van Rongen Aet al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012 ; 51 : 277–304. [PubMed] [Google Scholar]
  4. Hanley MJ, Abernethy DR, Greenblatt DJEffect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010 ; 49 : 71–87. [PubMed] [Google Scholar]
  5. Ciangura C, Bouillot JL, Lloret-Linares Cet al. Dynamics of change in total and regional body composition after gastric bypass in obese patients. Obesity 2010 ; 18 : 760–765. [Google Scholar]
  6. Chumlea WC, Guo SS, Zeller CMet al. Total body water reference values and prediction equations for adults. Kidney Int 2001 ; 59 : 2250–2258. [PubMed] [Google Scholar]
  7. Poirier P, Giles TD, Bray GAet al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss : an update of the 1997 American heart association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. Circulation 2006 ; 113 : 898–918. [PubMed] [Google Scholar]
  8. Edholm D, Kullberg J, Haenni Aet al. Preoperative 4-week low-calorie diet reduces liver volume and intrahepatic fat, and facilitates laparoscopic gastric bypass in morbidly obese. Obes Surg 2011 ; 21 : 345–350. [PubMed] [Google Scholar]
  9. Ribstein J, du Cailar G, Mimran ACombined renal effects of overweight and hypertension. Hypertension 1995 ; 26 : 610–615. [PubMed] [Google Scholar]
  10. Valensi P, Assayag M, Busby Met al. Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 1996 ; 20 : 574–579. [PubMed] [Google Scholar]
  11. Fabbrini E, Sullivan S, Klein SObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010 ; 51 : 679–689. [PubMed] [Google Scholar]
  12. Lumeng CN, Saltiel ARInflammatory links between obesity and metabolic disease. J Clin Invest 2011 ; 121 : 2111–2117. [PubMed] [Google Scholar]
  13. Tilg H, Kaser AGut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011 ; 121 : 2126–2132. [PubMed] [Google Scholar]
  14. Westhoff CL, Torgal AH, Mayeda ERet al. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010 ; 81 : 474–480. [PubMed] [Google Scholar]
  15. Westhoff CL, Torgal AH, Mayeda ERet al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol 2010 ; 116 : 275–283. [PubMed] [Google Scholar]
  16. Luo D, Westhoff CL, Edelman ABet al. Altered pharmacokinetics of combined oral contraceptives in obesity – multistudy assessment. Contraception. 2019 ; 99 : 256–263. [PubMed] [Google Scholar]
  17. Westhoff CL, Reinecke I, Bangerter K, Merz MImpact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene : a multicenter, open-label, uncontrolled study over three treatment cycles. Contraception 2014 ; 90 : 272–279. [PubMed] [Google Scholar]
  18. Westhoff CL, Torgal AH, Mayeda ER, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol 2012; 207 : 39.e1-6. [Google Scholar]
  19. Grimes DA, Shields WCFamily planning for obese women: challenges and opportunities. Contraception 2005 ; 72 : 1–4. [PubMed] [Google Scholar]
  20. Trussell J, Schwarz EB, Guthrie KObesity and oral contraceptive pill failure. Contraception 2009 ; 79 : 334–338. [PubMed] [Google Scholar]
  21. Holt VL, Cushing-Haugen KL, Daling JRBody weight and risk of oral contraceptive failure. Obstet Gynecol 2002 ; 99 : 820–827. [PubMed] [Google Scholar]
  22. Trussell J, Schwarz EB, Guthrie KObesity and oral contraceptive pill failure. Contraception 2009 ; 79 : 334–338. [PubMed] [Google Scholar]
  23. Holt VL, Scholes D, Wicklund KGet al. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005 ; 105 : 46–52. [PubMed] [Google Scholar]
  24. Lopez LM, Bernholc A, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2016; CD008452. [PubMed] [Google Scholar]
  25. Zieman M, Guillebaud J, Weisberg Eet al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002 ; 77 : S13–S18. [PubMed] [Google Scholar]
  26. Huber J, Wenzl RPharmacokinetics of Implanon. An integrated analysis. Contraception 1998 ; 58 : S85–S90. [Google Scholar]
  27. Xu H, Wade JA, Peipert JFet al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012 ; 120 : 21–26. [PubMed] [Google Scholar]
  28. Robinson JA, Burke AEObesity and hormonal contraceptive efficacy. Womens Health (Lond) 2013 ; 9 : 453–466. [PubMed] [Google Scholar]
  29. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Lancet 1995; 346 : 1582–8. [PubMed] [Google Scholar]
  30. Pomp ER, le, CS, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007 ; 139 : 289–296. [PubMed] [Google Scholar]
  31. Skeith L, Le Gal G, Rodger MA. contraceptives and hormone replacement therapy : How strong a risk factor for venous thromboembolism? Thromb Res Oral 2021; 202 : 134–8. [Google Scholar]
  32. Tanis BC, van den Bosch MA, Kemmeren JMet al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001 ; 345 : 1787–1793. [PubMed] [Google Scholar]
  33. WHO. Medical eligibility criteria for contraceptive use. A WHO family planning cornerstone, 5e ed. Geneva : World Health Organization, 2015. [Google Scholar]
  34. Ciangura C, Coupaye M, Deruelle Pet al. Clinical practice guidelines for childbearing female candidates for bariatric surgery, pregnancy, and post-partum management after bariatric surgery. Obes Surg 2019 ; 29 : 3722–3734. [PubMed] [Google Scholar]
  35. Sjöström L.Review of the key results from the Swedish obese subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med 2013 ; 273 : 219–234. [PubMed] [Google Scholar]
  36. Thereaux J, Veyrie N, Barsamian Cet al. Similar postoperative safety between primary and revisional gastric bypass for failed gastric banding. JAMA Surg 2014 ; 149 : 780–786. [PubMed] [Google Scholar]
  37. Ciangura C, Bouillot JL, Lloret-Linares Cet al. Dynamics of change in total and regional body composition after gastric bypass in obese patients. Obesity 2010 ; 18 : 760–765. [Google Scholar]
  38. Padwal R, Brocks D, Sharma AMA systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010 ; 11 : 41–50. [PubMed] [Google Scholar]
  39. Padwal RS, Ben-Eltriki M, Wang Xet al. Effect of gastric bypass surgery on azithromycin oral bioavailability. J Antimicrob Chemother 2012 ; 67 : 2203–2206. [PubMed] [Google Scholar]
  40. Padwal RS, Gabr RQ, Sharma AMet al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care 2011 ; 34 : 1295–1300. [PubMed] [Google Scholar]
  41. Hamad GG, Helsel JC, Perel JMet al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry 2012 ; 169 : 256–263. [PubMed] [Google Scholar]
  42. Angeles PC, Robertsen I, Seeberg LTet al. The influence of bariatric surgery on oral drug bioavailability in patients with obesity: a systematic review. J Obes Rev 2019 ; 20 : 1299–1311. [Google Scholar]
  43. Ciangura C, Corigliano N, Basdevant Aet al. Etonorgestrel concentrations in morbidly obese women following Roux-en-Y gastric bypass surgery: three case reports. Contraception 2011 ; 84 : 649–651. [PubMed] [Google Scholar]
  44. Moreira de Brito C, de Melo ME, Mancini MC, et al. Pharmacokinetics of oral levonorgestrel and ethinylestradiol in women after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2021; 17 : 673–81. [PubMed] [Google Scholar]
  45. Ginstman C, Frisk J, Carlsson Bet al. Plasma concentrations of etonogestrel in women using oral desogestrel before and after Roux-en-Y gastric bypass surgery: a pharmacokinetic study. BJOG 2019 ; 126 : 486–492. [PubMed] [Google Scholar]
  46. Madden S, Back DJ, Martin CA, Orme MLMetabolism of the contraceptive steroid desogestrel by the intestinal mucosa. Br J Clin Pharmacol 1989 ; 27 : 295–299. [PubMed] [Google Scholar]
  47. Chabbert-Buffet N, Marret H, Agostini Aet al. Clinical practice guidelines for contraception by the French national college of gynecologists and obstetricians (CNGOF). J Gynecol Obstet Hum Reprod 2019 ; 48 : 441–454. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.